NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free ATOS Stock Alerts $1.20 -0.03 (-2.03%) (As of 03:41 PM ET) Add Compare Share Share Today's Range$1.20▼$1.2450-Day Range$1.20▼$1.8752-Week Range$0.62▼$2.31Volume453,816 shsAverage Volume1.30 million shsMarket Capitalization$151.54 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Atossa Therapeutics alerts: Email Address Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside375.2% Upside$5.75 Price TargetShort InterestBearish8.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 4 Articles This WeekInsider TradingAcquiring Shares$44,250 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector727th out of 917 stocksPharmaceutical Preparations Industry344th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Atossa Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.92% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Atossa Therapeutics has recently decreased by 2.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 3.4 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows4 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,250.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions.Read more about Atossa Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.Learn More Today About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesJune 14 at 2:56 AM | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Stock Passes Above 200 Day Moving Average of $1.20June 8, 2024 | americanbankingnews.comAscendiant Capital Markets Increases Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.25June 7, 2024 | investorplace.comMeme Mania Meets Medicine: 3 Biotech Stocks Primed to SoarJune 5, 2024 | globenewswire.comAtossa to Present at the Sidoti Small-Cap Investor ConferenceJune 4, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200-Day Moving Average of $1.17May 28, 2024 | globenewswire.comAtossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelMay 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 17, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 15, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | proactiveinvestors.comAtossa Therapeutics gives final dose in breast cancer prevention studyMay 15, 2024 | globenewswire.comAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialMay 15, 2024 | markets.businessinsider.comAtossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy RatingMay 13, 2024 | msn.comAtossa Therapeutics files for $100M mixed shelf offeringMay 13, 2024 | msn.comATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024May 13, 2024 | finance.yahoo.comAtossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns with Analyst Projections Amidst ...May 13, 2024 | proactiveinvestors.comAtossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1May 13, 2024 | globenewswire.comAtossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | investorplace.comShhh! 3 Secret Penny Stocks Flying Below Wall Street's RadarMay 7, 2024 | proactiveinvestors.comAtossa Therapeutics welcomes updated breast cancer screening guidelinesMay 7, 2024 | globenewswire.comAtossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesApril 29, 2024 | globenewswire.comAtossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenApril 16, 2024 | insidermonkey.com5 Micro-Cap Healthcare Stocks Insiders Are BuyingApril 15, 2024 | markets.businessinsider.comPromising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer TreatmentApril 15, 2024 | proactiveinvestors.comAtossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugApril 15, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/14/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees12Year Founded2009Price Target and Rating Average Stock Price Target$5.75 High Stock Price Target$6.25 Low Stock Price Target$5.00 Potential Upside/Downside+367.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.79% Return on Assets-31.25% Debt Debt-to-Equity RatioN/A Current Ratio16.34 Quick Ratio16.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.68Miscellaneous Outstanding Shares125,760,000Free Float116,199,000Market Cap$154.68 million OptionableOptionable Beta1.19 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 73)M.D., Ph.D., Chairman, CEO & President Comp: $1.21MMs. Heather Rees CPA (Age 51)Senior VP of Finance & Principal Accounting Officer Comp: $520.64kMs. Delly Behen P.H.R.Senior Vice President of Administration & HRMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsAB Corporate Bond ETFNASDAQ:EYEGJaguar HealthNASDAQ:JAGXTetraphase PharmaceuticalsNASDAQ:TTPHArbutus BiopharmaNASDAQ:ABUSLarimar TherapeuticsNASDAQ:LRMRView All CompetitorsInsiders & InstitutionsCetera Advisors LLCBought 39,898 shares on 5/24/2024Ownership: 0.032%Virtu Financial LLCBought 83,941 shares on 5/20/2024Ownership: 0.067%Vanguard Group Inc.Bought 78,269 shares on 5/10/2024Ownership: 4.592%PFG Investments LLCBought 23,650 shares on 4/22/2024Ownership: 0.019%Jonathan FinnBought 25,000 shares on 4/10/2024Total: $44,250.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions Should I buy or sell Atossa Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks. What is Atossa Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1 year target prices for Atossa Therapeutics' stock. Their ATOS share price targets range from $5.00 to $6.25. On average, they anticipate the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 375.2% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts. How have ATOS shares performed in 2024? Atossa Therapeutics' stock was trading at $0.88 at the beginning of 2024. Since then, ATOS stock has increased by 37.5% and is now trading at $1.21. View the best growth stocks for 2024 here. When is Atossa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ATOS earnings forecast. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) issued its earnings results on Monday, May, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. When did Atossa Therapeutics' stock split? Atossa Therapeutics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK). Who are Atossa Therapeutics' major shareholders? Atossa Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.59%), Virtu Financial LLC (0.07%), Cetera Advisors LLC (0.03%), PFG Investments LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gregory L Weaver and Jonathan Finn. View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATOS) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.